PROX2

Across TCGA pan-cancer cohorts, PROX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PROX2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PROX2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated PROX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, SCLC, and COAD are the cancer types where PROX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.651	.011	30	view →
SCLC	DFS	Median	All	0.164	0.632	.003	27	view →
COAD	OS	Median	All	0.001	0.871	<.001	24	view →
STAD	DFS	Median	II,III,IV	1.000	0.631	.041	2	view →
SKCM	OS	Median	All	0.992	0.866	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PROX2–UCEC (OS)

Open the UCEC breakdown →